Citations

Clear

95 citation(s) found for "Strong, S A".

The role of artificial intelligence in developing meal plans in outpatient dietetics: A feasibility and proof of concept study
Mundi, Manpreet S. , Johnson, Danelle A., Schäfer, C., Theiler, Jami L., Ewoldt, Jason, Strong, Madelynn, Zeratsky, Katherine, Clinton, Angie M., Wolf, Sara Y., Mohamed Elfadil, Osman , Schafer, Christopher, Mundi, Manpreet S , Elfadil, Osman Mohamed , Schafer, Christopher, Zeratsky, Katherine, Clinton, Angie, Hurt, Ryan T.

Mayo Clinic

Nutrition in Clinical Practice | August 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ncp.70169 | PMID 42613785 Get It

Abstract Background Personalized meal planning by registered dietitian nutritionists (RDNs) is time‐intensive. Large language models (LLMs) may automate drafting meal plans, but their nutritional accuracy in clinical practice is uncertain. Methods In this proof‐of‐concept study, five outpatient RDNs and four LLMs (Gemini, CoPilot, ChatGPT 4.0, and customized ChatGPT 4.0) each generated 3‐day meal plans for five validated clinical scenarios. Effectiveness was defined as accuracy in meeting pre‐specified energy, protein, carbohydrate, fat, and sodium targets. Time to create plans and RDN comfort (self‐rated confidence in nutritional accuracy and clinical appropriateness on 1–5 Likert scale) were recorded. Three independent RDNs, blinded to source, analyzed nutrient content using Nutritionist Pro. Group differences were assessed with t ‐test and ANOVA. Results All LLMs and RDNs produced feasible meal plans. LLMs generated meal plans in under 1 min, whereas RDNs required a mean of 44 min per scenario. RDNs reported comfort levels ranging from 3.8 to 4.8. Across most scenarios, LLM plans delivered a smaller proportion of requested energy than RDN plans, which more consistently approached energy targets. Both groups performed similarly for the Mediterranean diet scenario. Overall, protein accuracy did not differ. However, in chronic kidney disease, LLMs undershot the guideline‐based protein target, while RDNs tended to modestly exceed it. Accuracy for low‐carbohydrate, fat, and sodium diets was comparable. Conclusion LLMs can rapidly generate clinically plausible meal plans but are less reliable than RDNs in achieving prescribed energy and selected macronutrient goals. Prompt precision is essential for nutrient‐specific targets. A hybrid model in which RDNs refine LLM‐generated drafts may leverage efficiency without sacrificing clinical accuracy.
International development of Investigator Global Assessment scores for pemphigus
Murrell, Dédée F., Boucher, Darby , Daneshpazhooh, Maryam, Mahmoudi, H., Kianfar, Nika , Wilson, Anna , BILGIC, ASLI, Chandran, N. S., Patsatsi, Aikaterini , Caux, Frédéric, Lim, Yen L., Marzano, Angelo V., Payne, Aimee S., Sprecher, Eli, Beek, Nina Van, Yamagami, Jun , Antiga, Emiliano, Bagci, I., Borradori, Luca, Caproni, Marzia, De, Dipankar, Dunn, Patrick F. , Feliciani, Claudio, Fivenson, David , Handa, Sanjeev, Horvath, B., Ioannides, D. , Kasperkiewicz, Michael, Lipman, Rachel E. , Mascaró, José M., Meijer, Joost M. , MIMOUNI, D, Schultz, Brittney , Skiljevic, Dusan, Strong, Becky, Tomayko, Mary M. , Vestergaard, Christian , Wozniak, Katarzyna, Yayli, S., Joly, Pascal, Werth, Victoria P., Caproni, Marzia , Joly, P. , Horváth, Barbara , Murrell, D F , Daneshpazhooh, M , Mahmoudi, Hamidreza , Wilson, Anna , Patsatsi, Aikaterini , Drenovska, Kossara , Caux, Frédéric , Marzano, Angelo Valerio , Schmidt, Enno , Sprecher, Eli , Van Beek, Nina , Antiga, Emiliano , Borradori, Luca , Caproni, Marzia , Feliciani, Claudio , Ioannides, Dimitrios , Kasperkiewicz, Michael , Mascaró, José M , Meijer, Joost M , Schultz, Brittney , Vestergaard, Christian , Joly, Pascal , Dasdar, Shayan , Yale, Marc , Uzun, Soner , Vassileva, Snejina , Culton, Donna Aline , Hertl, Michael , Marinović, Branka , Marzano, Angelo Valerio , Payne, Aimee S. , Schmidt, Enno , Sprecher, Eli , Bağci, Işın Sinem , Corrà, Alberto , De, Dipankar , Dunn, Patrick, Günther, Claudia , Handa, Sanjeev , Kowaléwski, Cezary , Lehman, Julia S. , Mimouni, Daniel , Skiljevic, Dusan S. , Woźniak, Katarzyna , Yaylı, Savaş , Werth, Victoria P.

Mayo Clinic

Journal of the European Academy of Dermatology and Venereology | April 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/jdv.70430 | PMID 41944632 Get It

555: EVALUATION OF EMERGENCY MEDICINE PHARMACIST PARTICIPATION IN TIME TO ANTICOAGULATION REVERSAL
Brown, Caitlin, Engstrom, Kellyn , Gilbert, Brian, Mattson, Alicia, Cole, Kristin, Acquisto, Nicole, Wieuruszewski, Erin, Mercer, Kevin, Rabinstein, Alejandro, Gilbert, Brian W. , Bellolio, Fernanda , Faine, Brett , Acquisto, Nicole M. , Mercer, Kevin, Rabinstein, Alejandro A.

Mayo Clinic

Critical Care Medicine | March 24, 2026 | Volume: 54 | Issue: 3S | Pages: No page available

10.1097/01.ccm.0001184216.00454.4d Get It

Cardiac radiotherapy–induced epigenetic memory underlies electrophysiologic and metabolic reprogramming
Jordan, Samuel D. , Fu, Shuhua, Fulkerson, Abigail, Hu, Donghua , Ng, Sherwin, Zhang, David M. , Manikandan, Sneha , Hu, Nan, Xie, Yuqian, Bedi, Anish, Tabor, James , Boggs-Bailey, Lauren, Strong, Lori, Hicks, Stephanie, Aryan, Lavanya, Gabriel, Nishanth , Hugo, Geoffrey D. , Weng, Kuo-Chan, Schwarz, Julie K. , zhang, bo , Rentschler, Stacey , Szymanski, Jeffrey, Szymanski, Jeffrey J. , Aryan, Lavanya , Huebsch, Nathaniel

Mayo Clinic

Journal of Clinical Investigation | February 17, 2026 | Volume: 136 | Issue: 7 | Pages: No page available

10.1172/jci193087 | PMID 41701534 Get It

Stereotactic arrhythmia radiotherapy (STAR) is emerging as a highly effective treatment for ventricular tachycardia (VT). Growing evidence indicates that STAR favorably reprograms the electrical substrate by speeding conduction and/or prolonging repolarization via modulation of ion channel expression, although the mechanisms by which single-fraction radiation mediates durable changes in gene expression are incompletely understood. Here, we identify dynamic changes in the cardiomyocyte epigenome and transcriptome after irradiation (IR) in vivo and in vitro, including durably increased expression and chromatin accessibility of Scn5a (encodes the α subunit of the sodium channel, Na V 1.5), demonstrating a role for epigenetic memory in conduction velocity (CV) increases observed after STAR. Transcriptomic and epigenetic sequencing further identified dynamic changes in gene expression and regulatory regions involved in cellular repolarization, calcium handling, and metabolism after IR. These changes were mirrored by dose-dependent and cell-autonomous changes in repolarization, calcium flux, and mitochondrial respiration, highlighting important cellular processes that may mediate the therapeutic effects of STAR. Overall, we found that cardiomyocytes exposed to a single fraction of high-dose IR exhibited epigenetic reprogramming that mediated broad and dynamic physiologic responses.
Planning Ahead: Residents’ Guide to Building a Strong Financial Future
Azhideh, Arash , Ozcan, B. Bersu , Miao, Julia H. , Anderson, Jacqueline Kunzelman , Brun‐Vergara, Maria Lucia , Kunzelman Anderson, Jacqueline

Mayo Clinic

RadioGraphics | December 11, 2025 | Volume: 46 | Issue: 1 | Pages: No page available

10.1148/rg.250004 | PMID 41379652 Get It

Rebuttal to: Hakim and Narouze; To trial pending strong evidence for otherwise
D’Souza, Ryan S. , Yu, Yue , Hussain, Nasir , Karri, Jay , Hussain, Nasir , D'Souza, Ryan S , Karri, Jay

Mayo Clinic

Regional Anesthesia & Pain Medicine | November 27, 2025 | Volume: No volume available | Issue: No issue available | Pages: rapm-2025-107412

10.1136/rapm-2025-107412 | PMID 41309155 Get It

Plasma Phosphorylated Tau 217 to Identify Preclinical Alzheimer Disease
Janelidze, Shorena, Bali, Divya , Dolado, Anna Orduña , Binette, Alexa Pichet , Rahmouni, Nesrine , Blennow, Kaj, Doré, Vincent , Feizpour, Azadeh , Rowe, Christopher C., Villeneuve, Sylvia , Petersen, Ronald C., Jack, Clifford R. , Groups, ADNI, ALFA, and PREVENT-AD Study, Adegoke, Olusegun, Hussen, Kedir Adem, Aisen, Paul, Ajayi, Adeyinka, Amaza, Hannatu, Apostolova, Liana G. , Ashford, Miriam T. , Ayo, Omobolanle, Bernard, Marie , Bernhardt, Haley, Boatwright, Virginia, Borowski, Bret, Brylska, Magdalena, Buckholtz, Neil, Cabrera, Yuliana, Cairns, Nigel J. , Carrillo, Maria, Choe, Mark, Clanton, Taylor, Conti, Cat, Craft, Hannah, Crawford, Karen , DeCarli, Charles , Benedetto, Joseph Di, Diaz, Adam , Drake, Erin, Faber, Kelley, Felmlee, Joel P. , Fidell, Andrea, Flenniken, Derek , Fockler, Juliet , Forghanian-Arani, Arvin, Frank, R.T., Franklin, Erin , Glittenberg, Matt, Gunter, Jeff, Guzmán, Vanessa , Harvey, Danielle, Hedberg, Caitie, Hergesheimer, Lindsey, Hoang, Isabella, Jackson, Jonathan , Jagust, William, Jahanshad, Neda , Jenkins, Cecily, Jiménez, Gustavo , Jin, Chengshi , Kachaturian, Zaven, Kaddurah-Daouk, Rima, Kantarci, Kejal, Karlawish, Jason , Khachaturian, Zaven S., Knaack, Alexander , Korecka, Magdalena , Kormos, Adrienne, Germano, Kaori Kubo, Kwang, Winnie, Lacy, Kaci, Landau, Susan, Lopresti, Brian J. , Magana, Fabiola, Mahboubi, Payam, Malone, Ian G., Masliah, Eliezer , Masterman, Donna, Matoush, Leonard, Miller, Melanie J. , Molchan, Susan, Montine, Tom, Moore-Weiss, John, Neu, Scott, Nosheny, Rachel L. , Ogwang, Sheila, Okonkwo, Ozioma, Parkins, Shaniya, Perrin, Richard J. , Petersen, Ronald, Pizzola, Jeremy, Potter, Zoë, Potter, William Z., Rafii, Michael, Raman, Rema , Reyes, Calvin, Reyes, Denise , Robison, Justin , Chen, Stephanie Rossi, Ryan, Laurie, Sachdev, Pallavi, Saito, Naomi , Salazar, Jennifer, Thao, Mai Seng, Shaffer, Elizabeth , Shaw, Leslie M. , Silverberg, Nina, Strong, Joe, Talavera, Sandra , Taylor‐Reinwald, Lisa, Thal, Leon J., Thomas, Lisa , Thompson, Paul , Tosun, Duygu , Trojanowki, John Q., Sacrey, Diana Truran, Villemagne, Victor L. , Walter, Sarah , Wan, Yang , Ward, Chad, Webb, Caitlin, Weiner, Michael W. , Weisensel, Trinity, Zimmerman, Caileigh, Poirier, Judes, Breitner, John C.S. , Badawy, Mohamed , Baril, Andrée‐Ann, Aguilar, Ricardo A, Gorriti, Annabella B, Gispert, Lidia C, Martinez, Alba C, Iglesias, Ruth D, Julian, Sherezade F, Serra, P, González‐Escalante, Armand , Penas, Laura H, Rodriguez, Gema H, Ninou, Jordi H, Gamaz, Laura Iglesias, Knezevic, Iva, Alvarez, Paula M, Diaz, Tania M, Palacios, Eva , Ballester, A, Mendez, Sandra P, Freixedes, Laura Ros, Vila, Aleix S, Harster, Lluis S, Prat, Anna S, Jaramillo, Marc V, Jack, Clifford R , Feizpour, Azadeh , Doré, Vincent , Pichet Binette, Alexa , Salvadó, Gemma , Janelidze, Shorena , Therriault, Joseph , Brum, Wagner Scheeren , Stomrud, Erik , Mattsson, Niklas , Palmqvist, Sebastian , Coomans, Emma M. , Teunissen, Charlotte E. , Flier, Wiesje M. van der , Benzinger, Tammie L.S. , Gispert, Juan Domingo , Blennow, Kaj , Alcolea, Daniel , Fortea, Juan , Johnson, Sterling C. , Rosa-Neto, Pedro , Schindler, Suzanne E. , Suárez‐Calvet, Marc , Ossenkoppele, Rik , Hansson, Oskar , Groups, ADNI, ALFA, and PREVENT-AD Study, Aisen, Paul , Barnes, Lisa L. , Beckett, Laurel , Das, Sandhitsu R. , Donohue, Michael , Drake, Erin, Erickson, Claire M. , Fletcher, Evan M. , Arani, Arvin , Foroud, Tatiana , Fox, Nick C. , Frank, Richard, González, Hector, Green, Robert C. , Grill, Joshua D. , Harkins, Kristin , Ho, Carole , Hsiao, John , Jo, Taeho, Kaddurah‐Daouk, Rima , Kantarci, Kejal , Koeppe, Robert A. , Largent, Emily A. , Lee, Edward B. , Lee, Virginia M.‐Y. , Morris, John C. , Nho, Kwangsik T. , Nir, Talia M. , Nudelman, Kelly , Okonkwo, Ozioma, Petersen, Ronald, Rabinovici, Gil D. , Rafii, Michael S. , Reid, Robert, Reyes, Denise, Risacher, Shannon L. , Mindt, Mónica Rivera , Sachdev, Pallavi, Saykin, Andrew J. , Schwarz, Christopher G. , Senjem, Matthew L. , Li, Shen , Smith, Stephanie R. , Snyder, Peter J. , Thomopoulos, Sophia I. , Toga, Arthur W. , Vemuri, Prashanthi , Yushkevich, Paul A. , Badawy, Mohamed, Baillet, Sylvain , Minguillón, Carolina , Brugulat‐Serrat, Anna , Cacciaglia, Raffaele , Campo, Marta del , Pascual, Maria, Rodríguez‐Fernández, Blanca , Vilor‐Tejedor, Natàlia

Mayo Clinic

JAMA Neurology | September 15, 2025 | Volume: 82 | Issue: 11 | Pages: 1122

10.1001/jamaneurol.2025.3217 | PMID 40952756 Get It

Importance Advances in Alzheimer disease (AD) have shifted research focus to earlier disease stages, necessitating more scalable approaches to identify cognitively unimpaired individuals with amyloid β (Aβ) pathology. Objective To assess the utility of plasma phosphorylated tau 217 (p-tau217) for classifying Aβ status in cognitively unimpaired individuals, both as a stand-alone test and in a 2-step approach where positive plasma results were confirmed using a second modality (Aβ positron emission tomography [PET] or cerebrospinal fluid [CSF]). Design, Setting, and Participants This cross-sectional cohort study used data collected between June 2009 and March 2024. We included 2916 cognitively unimpaired participants from 12 international independent observational cohorts in the US, Europe, Australia, and Canada with available plasma p-tau217 levels and CSF or PET Aβ biomarkers. Performance comparisons between mass spectrometry and immunoassay-based p-tau217 measurements were also performed (n = 964). Exposures Plasma p-tau217 levels measured by immunoassay. Main Outcome and Measures Aβ status, determined by CSF or Aβ PET biomarkers. Results Participants had a mean (SD) age of 66.9 (9.9) years; 971 (33.3%) were Aβ positive by either CSF or PET, 1667 (57.2%) were women, and 1108 (38.1%) carried at least 1 APOE ε4 allele. As a stand-alone test, plasma p-tau217 achieved a positive predictive value (PPV) of 79% (95% CI, 74-84) and an overall accuracy of 81% (95% CI, 80-82). In a 2-step workflow, the PPV and accuracy significantly increased to 91% (95% CI, 86-95). While this approach required screening of 677 individuals with plasma p-tau217 to identify 100 Aβ-positive individuals, compared to 536 participants when using PET alone, it reduced the need for PET testing to 124. Immunoassays demonstrated comparable PPVs to mass spectrometry (80% [95% CI, 74-86] vs 85% [95% CI, 81-90]; P = .12) but significantly lower overall accuracy (82% [95% CI, 79-84]% vs 88 [95% CI, 86-90]; P < .001) and true Aβ-positive detection rate (49% [95% CI, 43-55] vs 69% [95% CI, 64-75]; P < .001). Conclusions and Relevance The findings highlight the potential of plasma p-tau217 as a stand-alone test—or when used in a sequential 2-step approach alongside PET or CSF testing—as a cost-effective, scalable, and minimally burdensome strategy for identifying preclinical AD. Tailored screening workflows that incorporate p-tau217 can improve efficiency in participant selection for preclinical AD trials and, in the future, help guide access to disease-modifying treatments.
Letter to the Editor: Reply to “Population Screening for Cirrhosis” by Thiele et al, describing the Florida Healthy Liver Program
Ryland, Kristen, Harnois, Denise M. , Strong, Cyneetha, Whiddon, George, Mulrooney, Christopher, Littles, Alma B., Toskich, Beau , Ryland, Kristen L, Garza‐Ramos, Cynthia De la , Patel, Tushar , Mulrooney, Christopher

Mayo Clinic

Hepatology Communications | June 9, 2025 | Volume: 9 | Issue: 7 | Pages: No page available

10.1097/hc9.0000000000000713 | PMID 40489755 Get It

Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Ajani, Jaffer A. , D’Amico, Thomas A., Bentrem, David J., Corvera, Carlos U. , Das, Prajnan , Enzinger, Peter C. , Enzler, Thomas , Gerdes, Hans, Grierson, Patrick , Hofstetter, Wayne L. , Ilson, David H. , Jalal, Shadia I. , Kleinberg, Lawrence , Lacy, Jill , Lee, Byrne , Licciardi, Frank, Ly, Quan P. , Matsukuma, Karen , McNamara, Michael, Mukherjee, Sarbajit , Mulcahy, Mary F. , Reddi, Deepti , Reznik, Scott I. , Roses, Robert E. , Strong, Vivian E. , Su, Stacey, Uboha, Nataliya V. , Willett, Christopher G. , Yoon, Harry H. , McMillian, Nicole R., Stein, MaryElizabeth , Gupta, Garima , Ajani, Jaffer A , Bentrem, David J. , Gibson, Michael K. , Gupta, Garima , Kim, Sunnie S. Y. , Klempner, Samuel J. , Lloyd, Shane , Merkow, Ryan P. , Perry, Kyle A. , Pimiento, José M. , Reddi, Deepti , Wainberg, Zev A. , Woo, Yanghee

Mayo Clinic

Journal of the National Comprehensive Cancer Network | May 8, 2025 | Volume: 23 | Issue: 5 | Pages: 169-191

10.6004/jnccn.2025.0022 | PMID 40341199 Get It

Gastric cancer is the fifth leading cause of cancer-related deaths worldwide. Over 95% of gastric cancers are adenocarcinomas, which are typically classified based on anatomic location and histologic type. Gastric cancer generally carries a poor prognosis because it is often diagnosed at an advanced stage. Systemic therapy can provide palliation, improve survival, and enhance the quality of life in patients with locally advanced or metastatic disease. The implementation of biomarker testing has had a significant impact on clinical practice and patient care. Targeted therapies have demonstrated encouraging results in clinical trials for the treatment of patients with locally advanced or metastatic disease. This selection from the NCCN Clinical Practice Guidelines in Oncology for Gastric Cancer highlights recommendations for biomarker testing and discusses updates for the treatment of advanced disease, including peritoneal carcinoma as only disease and unresectable locally advanced, recurrent, or metastatic disease.
565 The design and operation of a robust clinical trials unit information system: 15 years strong and evolving
Lin, Michael, Wick, Joseph, Weis, Jennifer, Shea, Melinda, Park, Myung, Fan, Jiyuan, Tuseth, Holly, Lin, Michael, Shea, Melinda, Park, Myung

Mayo Clinic

Journal of Clinical and Translational Science | March 25, 2025 | Volume: 9 | Issue: s1 | Pages: 166-166

10.1017/cts.2024.1136 Get It

Objectives/Goals: The operation of a clinical trials unit involves multifaceted tasks and stakeholders. A competent information system is critical to daily operations while ensuring smooth conduct of clinical research. We share 15 years of experience in the design and implementation of such a system at Mayo Clinic to inform other institutions with similar interests. Methods/Study Population: The Informatics team collaborated closely with nurse leaders and elicited input from additional stakeholders including nurse unit coordinators, lab managers, schedulers, investigators, study coordinators, and regulatory specialists throughout the phases of system design, development and continuous enhancements, and expansion. The stakeholders offered insights on the corresponding requirements throughout the study life cycle, from engaging with the study sponsor, operational review for protocol execution, development of study budgets, human subject protection and risk mitigation, data management and integration, to outcome monitoring, and regulatory reporting. The activities were then translated into functional components and implemented as a seamless and effective solution. Results/Anticipated Results: Patient safety, scientific rigor, operation automation, efficiency, and regulatory requirements were all considered in developing an integrated system, or the clinical research trials unit (CRTU) Tools. Our institution has leveraged the system for essential tasks from the study start-up, visit scheduling and execution, specimen collection and tracking, to individual protocol metrics and billing. We adopted a measure-as-we-go methodology so that data such as visit census, resource usage, and protocol deviation are tracked and collected during routine use of the system. Specifically, an issues/concerns/exceptions (ICE) tool is used for quality control and patient safety. Moreover, data quality greatly benefits from a task dictionary, standardizing the study activities that can be ordered and executed. Discussion/Significance of Impact: The implementation of a well-rounded clinical trials unit information system not only improves the operation efficiency and team productivity but also ensures scientific rigor and contributes to patient safety. We believe the experience can be informative to other institutions. More details will be shared in the poster.